miRagen Therapeutics' Series B Round

miRagen Therapeutics raised a round of funding on April 24, 2012.

miRagen Therapeutics (NASDAQ: MGEN) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high u…

Articles about miRagen Therapeutics' Series B Round: